| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35d9ddd9f56e7f62be5d219a16cc62e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e72837de81999e7e72cb78d59d19e28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c144c00e661c30fb3ba0e82ffb9514a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-902
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-775 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2005-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46552e1dcb7e3815ba77d687cdbd4c0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ed6962e5a076a32c6d98cb61f7e051a |
| publicationDate |
2006-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006020498-A2 |
| titleOfInvention |
Therapeutic agents and methods for cardiovascular disease |
| abstract |
The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-l comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoAl peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11054389-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019182901-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9365888-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2268305-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022056336-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2366431-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2268305-A4 |
| priorityDate |
2004-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |